{
    "ticker": "PMCB",
    "name": "Puma Biotechnology, Inc.",
    "description": "Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products for the treatment of various forms of cancer. Founded in 2010 and headquartered in Los Angeles, California, Puma focuses on precision medicine and the development of targeted therapies that improve patient outcomes. The company's flagship product, NERLYNX (neratinib), is an oral treatment for patients with early-stage HER2-positive breast cancer, designed to help prevent disease recurrence after trastuzumab-based therapy. Puma's commitment to research and development is evidenced by its robust pipeline of investigational drugs, which aim to address unmet medical needs in oncology. The company collaborates with leading researchers and institutions to advance its therapeutic programs and is devoted to providing patients with access to effective cancer treatments. Puma Biotechnology is also focused on educating healthcare professionals about its products and the importance of personalized medicine in oncology. The company\u2019s mission is to improve the lives of cancer patients through innovation, dedication, and advocacy.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2010",
    "website": "https://www.pumabiotechnology.com",
    "ceo": "Alan H. Auerbach",
    "social_media": {
        "twitter": "https://twitter.com/PumaBiotech",
        "linkedin": "https://www.linkedin.com/company/puma-biotechnology-inc/"
    },
    "investor_relations": "https://investors.pumabiotechnology.com",
    "key_executives": [
        {
            "name": "Alan H. Auerbach",
            "position": "CEO"
        },
        {
            "name": "Richard L. L. G. J. H. Auerbach",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "NERLYNX (neratinib)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Puma Biotechnology, Inc. | Innovating Cancer Treatments",
        "meta_description": "Discover Puma Biotechnology, Inc., dedicated to the development of targeted cancer therapies. Learn about their innovative products and commitment to oncology.",
        "keywords": [
            "Puma Biotechnology",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "NERLYNX",
            "HER2-positive Breast Cancer"
        ]
    },
    "faq": [
        {
            "question": "What is Puma Biotechnology known for?",
            "answer": "Puma Biotechnology is known for developing innovative cancer therapies, particularly NERLYNX for HER2-positive breast cancer."
        },
        {
            "question": "Who is the CEO of Puma Biotechnology?",
            "answer": "Alan H. Auerbach is the CEO of Puma Biotechnology, Inc."
        },
        {
            "question": "Where is Puma Biotechnology headquartered?",
            "answer": "Puma Biotechnology is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What are Puma's main products?",
            "answer": "Puma's main product is NERLYNX (neratinib), an oral treatment for early-stage HER2-positive breast cancer."
        },
        {
            "question": "When was Puma Biotechnology founded?",
            "answer": "Puma Biotechnology was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GENZ",
        "MRNA"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}